{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T05:23:37Z","timestamp":1781760217175,"version":"3.54.5"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,6,22]],"date-time":"2017-06-22T00:00:00Z","timestamp":1498089600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100000801","name":"Bayer HealthCare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008648","name":"Pfizer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008648","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s11239-017-1519-8","type":"journal-article","created":{"date-parts":[[2017,6,22]],"date-time":"2017-06-22T08:32:47Z","timestamp":1498120367000},"page":"169-178","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Effectiveness and safety of apixaban therapy in daily-care patients with atrial fibrillation: results from the Dresden NOAC Registry"],"prefix":"10.1007","volume":"44","author":[{"given":"Sindy","family":"Helmert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Marten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Mizera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antje","family":"Reitter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurtulus","family":"Sahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luise","family":"Tittl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Beyer-Westendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,22]]},"reference":[{"issue":"38","key":"1519_CR1","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","volume":"37","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, Agewall S, Camm J, Baron Esquivias G, Budts W, Carerj S, Casselman F, Coca A, De Caterina R, Deftereos S, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorenek B, Guenoun M, Hohnloser SH, Kolh P, Lip GY, Manolis A, McMurray J, Ponikowski P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P, Tamargo JL, Taylor CJ, Van Gelder IC, Voors AA, Windecker S, Zamorano JL, Zeppenfeld K (2016) 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37(38):2893\u20132962","journal-title":"Eur Heart J"},{"issue":"5","key":"1519_CR2","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/europace\/eut083","volume":"15","author":"H Heidbuchel","year":"2013","unstructured":"Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P (2013) European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 15(5):625\u2013651","journal-title":"Europace"},{"issue":"11","key":"1519_CR3","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L, Committees A, Investigators (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365(11):981\u2013992. doi:\n                        10.1056\/NEJMoa1107039","journal-title":"N Engl J Med"},{"issue":"6","key":"1519_CR4","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1160\/TH14-11-0954","volume":"113","author":"J Beyer-Westendorf","year":"2015","unstructured":"Beyer-Westendorf J, Ebertz F, Forster K, Gelbricht V, Michalski F, Kohler C, Werth S, Endig H, Pannach S, Tittl L, Sahin K, Daschkow K, Weiss N (2015) Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. Thromb Haemost 113(6):1247\u20131257","journal-title":"Thromb Haemost"},{"issue":"5","key":"1519_CR5","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1160\/TH15-10-0840","volume":"115","author":"J Hecker","year":"2016","unstructured":"Hecker J, Marten S, Keller L, Helmert S, Michalski F, Werth S, Sahin K, Tittl L, Beyer-Westendorf J (2016) Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. Thromb Haemost 115(5):939\u2013949","journal-title":"Thromb Haemost"},{"issue":"4","key":"1519_CR6","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3(4):692\u2013694","journal-title":"J Thromb Haemost"},{"key":"1519_CR7","unstructured":"SmPC apixaban (2015) \n                        http:\/\/www.medicines.org.uk\/emc\/medicine\/24988\n                        \n                    . Accessed 06 January 2016"},{"issue":"5","key":"1519_CR8","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1160\/TH16-05-0403","volume":"116","author":"GY Lip","year":"2016","unstructured":"Lip GY, Keshishian A, Kamble S, Pan X, Mardekian J, Horblyuk R, Hamilton M (2016) Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis. Thromb Haemost 116(5):975\u2013986","journal-title":"Thromb Haemost"},{"key":"1519_CR9","doi-asserted-by":"crossref","first-page":"i3189","DOI":"10.1136\/bmj.i3189","volume":"353","author":"TB Larsen","year":"2016","unstructured":"Larsen TB, Skjoth F, Nielsen PB, Kjaeldgaard JN, Lip GY (2016) Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ 353:i3189","journal-title":"BMJ"},{"issue":"12","key":"1519_CR10","first-page":"907","volume":"38","author":"L Staerk","year":"2017","unstructured":"Staerk L, Fosbol EL, Lip GYH, Lamberts M, Bonde AN, Torp-Pedersen C, Ozenne B, Gerds TA, Gislason GH, Olesen JB (2017) Ischaemic and haemorrhagic stroke associated with non-vitamin K antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation: a nationwide cohort study. Eur Heart J 38(12):907\u2013915","journal-title":"Eur Heart J"},{"issue":"5","key":"1519_CR11","doi-asserted-by":"crossref","first-page":"e002758","DOI":"10.1136\/bmjopen-2013-002758","volume":"3","author":"R Sorensen","year":"2013","unstructured":"Sorensen R, Gislason G, Torp-Pedersen C, Olesen JB, Fosbol EL, Hvidtfeldt MW, Karasoy D, Lamberts M, Charlot M, Kober L, Weeke P, Lip GY, Hansen ML (2013) Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study. BMJ Open 3(5):e002758","journal-title":"BMJ Open"},{"issue":"14","key":"1519_CR12","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1093\/eurheartj\/ehv466","volume":"37","author":"AJ Camm","year":"2016","unstructured":"Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, Kuhls S, van Eickels M, Turpie AG (2016) XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J 37(14):1145\u20131153. doi:\n                        10.1093\/eurheartj\/ehv466","journal-title":"Eur Heart J"},{"key":"1519_CR13","doi-asserted-by":"crossref","first-page":"h1857","DOI":"10.1136\/bmj.h1857","volume":"350","author":"NS Abraham","year":"2015","unstructured":"Abraham NS, Singh S, Alexander GC, Heien H, Haas LR, Crown W, Shah ND (2015) Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ 350:h1857","journal-title":"BMJ"},{"issue":"6","key":"1519_CR14","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1160\/TH15-06-0453","volume":"114","author":"TC Villines","year":"2015","unstructured":"Villines TC, Schnee J, Fraeman K, Siu K, Reynolds MW, Collins J, Schwartzman E (2015) A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system. Thromb Haemost 114(6):1290\u20131298","journal-title":"Thromb Haemost"},{"issue":"1","key":"1519_CR15","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1160\/TH15-03-0247","volume":"115","author":"M Avgil-Tsadok","year":"2016","unstructured":"Avgil-Tsadok M, Jackevicius CA, Essebag V, Eisenberg MJ, Rahme E, Behlouli H, Pilote L (2016) Dabigatran use in elderly patients with atrial fibrillation. Thromb Haemost 115(1):152\u2013160","journal-title":"Thromb Haemost"},{"key":"1519_CR16","doi-asserted-by":"crossref","first-page":"j510","DOI":"10.1136\/bmj.j510","volume":"356","author":"PB Nielsen","year":"2017","unstructured":"Nielsen PB, Skjoth F, Sogaard M, Kjaeldgaard JN, Lip GY, Larsen TB (2017) Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ 356:j510","journal-title":"BMJ"},{"issue":"1","key":"1519_CR17","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/s12872-016-0438-5","volume":"16","author":"O Konigsbrugge","year":"2016","unstructured":"Konigsbrugge O, Simon A, Domanovits H, Pabinger I, Ay C (2016) Thromboembolic events, bleeding, and drug discontinuation in patients with atrial fibrillation on anticoagulation: a prospective hospital-based registry. BMC Cardiovasc Disord 16(1):254","journal-title":"BMC Cardiovasc Disord"},{"issue":"1","key":"1519_CR18","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/ehjcvp\/pvw031","volume":"3","author":"S Halvorsen","year":"2017","unstructured":"Halvorsen S, Ghanima W, Fride Tvete I, Hoxmark C, Falck P, Solli O, Jonasson C (2017) A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants. Eur Heart J Cardiovasc Pharmacother 3(1):28\u201336","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"1519_CR19","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1093\/eurheartj\/ehv721","volume":"37","author":"MR Fay","year":"2016","unstructured":"Fay MR, Martins JL, Czekay B (2016) Oral anticoagulant prescribing patterns for stroke prevention in atrial fibrillation among general practitioners and cardiologists in three European countries. Eur Heart J 37:510 (Abstract P2597)","journal-title":"Eur Heart J"},{"issue":"7","key":"1519_CR20","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1185\/03007995.2016.1170672","volume":"32","author":"E Nguyen","year":"2016","unstructured":"Nguyen E, White CM, Patel MR, Fields LE, Peacock WF, Crivera C, Coleman CI (2016) Doses of apixaban and rivaroxaban prescribed in real-world United States cardiology practices compared to registration trials. Curr Med Res Opin 32(7):1277\u20131279","journal-title":"Curr Med Res Opin"},{"key":"1519_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.03.027","volume-title":"Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants in patients without severe renal impairment","author":"X Yao","year":"2016","unstructured":"Yao X, Shah ND, Sangaralingham LR, Gersh BJ (2016) Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants in patients without severe renal impairment. Elsevier, Amsterdam. doi:\n                        10.1016\/j.jval.2016.03.027\n                        \n                    . Accessed 04 October 2016"},{"issue":"5","key":"1519_CR22","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1160\/th15-02-0116","volume":"114","author":"F Michalski","year":"2015","unstructured":"Michalski F, Tittl L, Werth S, Hansel U, Pannach S, Sahin K, Weiss N, Beyer-Westendorf J (2015) Selection, management, and outcome of vitamin K antagonist-treated patients with atrial fibrillation not switched to novel oral anticoagulants. Results from the Dresden NOAC registry. Thromb Haemost 114(5):1076\u20131084. doi:\n                        10.1160\/th15-02-0116","journal-title":"Thromb Haemost"},{"issue":"8","key":"1519_CR23","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1093\/europace\/euv421","volume":"18","author":"J Beyer-Westendorf","year":"2016","unstructured":"Beyer-Westendorf J, Ehlken B, Evers T (2016) Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation. Europace 18(8):1150\u20131157","journal-title":"Europace"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11239-017-1519-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-017-1519-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-017-1519-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,7,21]],"date-time":"2017-07-21T08:06:38Z","timestamp":1500624398000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11239-017-1519-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,22]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["1519"],"URL":"https:\/\/doi.org\/10.1007\/s11239-017-1519-8","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"value":"0929-5305","type":"print"},{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,22]]}}}